Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

North Bud Farms $NBUD.ca Enters U.S. Market with the Signing of the Definitive Agreement to Acquire Nevada Botanical Science Located in Reno, Nevada $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 8:59 AM on Tuesday, November 19th, 2019
  • Signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc.
  • Transaction valued at USD$7.5 million
  • NBS currently operates a 5,000 sq. ft. indoor cultivation facility and has been approved for expansion of up to 60,000 sq. ft of greenhouse space.
  • Property also includes an operating extraction facility and licensed and approved commercial kitchen.
  • This infrastructure is capable of manufacturing and bottling beverages and edibles and is currently used by NBS for both white label and branded product manufacturing.

TORONTO, Nov. 19, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has signed a definitive asset purchase agreement to acquire all assets of Nevada Botanical Science, Inc. (“NBS”) (see June 25, 2019 press release) in a transaction valued at USD$7.5 million.

Nevada Botanical Science (NBS) is located in Reno, Nevada. NBS holds Nevada State medical and adult use licenses for cultivation, extraction and distribution. NBS operates an integrated cannabis operation located on 3.2 acres of land within the Reno green zone industrial park. NBS currently operates a 5,000 sq. ft. indoor cultivation facility and has been approved for expansion of up to 60,000 sq. ft of greenhouse space. The property also includes an operating extraction facility and licensed and approved commercial kitchen. This infrastructure is capable of manufacturing and bottling beverages and edibles and is currently used by NBS for both white label and branded product manufacturing. Operated by healthcare professionals, NBS has been primarily focused on the Nevada State medical cannabis market. NBS currently manufactures and sells award winning (Jack Herer Cup 2018) topical pain creams, balms and lotions under the Trichomic medical brand.

This past year NBS launched a trial release of cannabis infused cocktails under the brand “Happiest Hour”. Collaborating with local craft beverage manufactures NBS released a variety of beverages including Margarita, Pina Colada, Bloody Mary, Long Island Ice Tea and Lemonade to select retailers in the state. To date retailer adoption and reordering has been 100% and based on customer feedback, NBS will increase production and distribution including additional retailers in Las Vegas in 2020. NBS has also finished a successful trial launch of its energy shot 1oz beverage containing 25mg of THC and 50mg of Caffeine. The Company plans to run a second branded trial in early 2020. Over the past three months NBS and NORTHBUD have been working together in preparation for the release of NORTHBUD branded dried flower products in Q4 2019 and a variety of infused and non-infused pre rolls. 

“Subject to the finalizing of the previously announced acquisition of the Qlora Group in California, the Company plans to establish a unified product manufacturing and distribution platform within these two important states,” said Justin Braune, President of Bonfire Brands USA. “The license classes in California and Nevada allow for identical activities and the Company has been in negotiation with multiple potential JV partners who wish to leverage this unique platform. Being one of the few multi state operators with operations in both states will allow us to offer turnkey solutions to prospective partners moving forward.”

Transaction Terms

The transaction (the “Transaction”) is structured as an asset purchase agreement whereby in exchange for the purchase of all of the securities and assets of NBS, NORTHBUD is paying a total of USD$7,500,000 as follows:

  • Cash payment of USD$500,000 (paid in full);
  • Approximately USD$1 million in convertible shares of Bonfire Brands USA (6,500,000 “convertible shares”); and
  • A USD$6,000,000 interest bearing promissory note.

The convertible shares may be exchanged on a 1-1 basis with common shares of NBUD at the discretion of the shareholder. At the time of signing, the converted value of these securities was equal to USD$1,000,000. All applicable U.S. and Canadian regulatory holds shall apply upon conversion.

As per the terms of the agreement NBS will allocate pro rated ownership of assets in NBS and all associated licenses to Bonfire Brands USA throughout the re-payment period, subject to state approval.

Bonfire Brands and NBS have agreed to an operations and management arrangement allowing Bonfire to assume operational control, begin integration and driving revenue immediately.  

“The NORTHBUD and Bonfire Brands USA team are extremely proud to have finalized this agreement making the state of Nevada our strategic entry point into the U.S. legal cannabis market,” said Ryan Brown, CEO of NORTHBUD. “We are equally proud of the structure of the deal and how it minimizes shareholder dilution while allowing our team to begin integration and operations with a focus on immediate revenue growth in one of the most sought-after adult use markets in North America. Our team has been looking at acquisitions in Nevada for over two years before finding the right fit.  The Nevada market is considered one of the largest and most profitable in North America with recreational sales of USD$580 million in the first full year of legalization* (2017 Nevada Dept. of Taxation).”

The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Transaction is a significant acquisition but will not result in a “Fundamental Change” pursuant to the policies of the CSE. NORTHBUD will be preparing the necessary corporate and securities filings in order to secure the required approvals for the Transaction.

The parties have agreed to pay USD$187,500 in broker/finder fees to arm’s length parties on a prorated basis connection with the closing of the Transaction.

The closing of the Transaction is conditional on the receipt by the parties of applicable corporate and regulatory approvals, including that of the CSE.

About Nevada Botanical Science, Inc.

Founded by a group of northern Nevada physicians and healthcare professionals who believe in the promise of medical cannabis, Nevada Botanical Science has developed a world class cannabis production, research and development facility in Reno’s Washoe County. Its work and commitment are fully in compliance with the Hippocratic Oath as well as Nevada statute. Nevada Botanical Science is dedicated to ensuring the highest measure of safety, governance and stewardship for its patients, employees and the community it serves.

For more information visit: www.nevadabotanicalscience.com

About North Bud Farms Inc.

North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act.  The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has acquired Nevada Botanical Science, Inc. a world class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation in Reno’s Washoe County. Nevada Botanical Science holds medical and adult use licenses for cultivation, extraction and distribution. Bonfire Brands USA has entered into an agreement to acquire assets in Salinas, California.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with Nevada Botanical Science, Inc. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

NORTHBUD $NBUD.ca – #THC – infused #edibles and #CBD – infused edibles $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 5:37 PM on Monday, November 18th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

THC-infused edibles and CBD-infused edibles

When cannabis is ingested, the THC is metabolized by the liver

With edibles coming to brick-and-mortar shops in mid-December, users are looking to get high without the smoke.

But when choosing edibles, users will want to pay attention to whether the product has CBD or THC, two compounds with very different effects.

CBD

CBD, the non-psychoactive component within cannabis has been widely touted for its medical benefits to help people with, among other conditions, chronic pain. The World Health Organization (WHO) reports CBD is not physically addictive.

By comparing those administered doses of active CBD to those given as a placebo, researchers said that “while the number of studies is limited, the evidence from well-controlled human experimental research indicates that CBD is not associated with abuse potential.”

CBD leads to slower effects that aren’t psychoactive in nature — meaning they aren’t the effects you see portrayed in pop culture.

The effects from CBD will be tame and mellow compared to its psychoactive opposite, THC. Most medical cannabis includes CBD rather than THC, with CBD already available in capsule form in legal stores.

THC

When most people think of cannabis’ effects, they think of THC. Many of the new cannabis products slated to enter stores in mid-December will focus on THC.

When cannabis is ingested, the THC is metabolized by the liver, transforming itself into 11-hydroxy-THC. This metabolite is up to four times faster in crossing the blood-brain barrier than average THC, and is why edibles are associated with intense, vivid and longer-lasting experiences.

THC normally gets pointed at as the compound that creates the potential for withdrawal symptoms among some heavy users.

An evidence brief compiled by the Canadian Public Health Association (CPHA) states that “cannabis is addictive, though not everyone who uses it will develop an addiction.”

While using cannabis oil or edibles with THC, users may get addicted or experience habit-formation. Products that only include CBD don’t appear to become addictive.

Source: https://lfpress.com/cannabis-news/day-29-thc-infused-edibles-and-cbd-infused-edibles/wcm/473a4264-5028-4c42-94ca-53da8b2db7c7

CLIENT FEATURE: Vertical Exploration $VERT.ca – Note Facility to Support Development at St-Onge Paving the Way for Wollastonite Exploitation $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 12:25 PM on Monday, November 18th, 2019
http://www.smallcapepicenter.com/Vert%20Square.png
VERT: v –

Vertical Exploration and Venturevest Realty Partners LLC have signed a non- binding Letter of Intent (LOI) to enter into discussions regarding a secured Note Facility up to a maximum amount of $20 million CAD to support the multi-phased development of the St-Onge Wollastonite Deposit.

A staged credit facility allowing Vertical to move forward with four distinct phases of St-Onge development, first establishing the initial quarry style permitting and production phase through to the mining and final processing plant stage.

https://vertxinc.com/wp-content/uploads/2018/01/Bitmap.png

What is Wollastonite?

  • Wollastonite is a chemically simple mineral named in honor of English mineralogist and chemist Sir W.H. Wollaston (1766–1828). It is composed of calcium (Ca) and silicon and oxygen (SiO2, silica) with the chemical formula CaSiO3. Although much wollastonite is relatively pure CaSiO3, it can contain some iron, magnesium, manganese, aluminum, potassium, sodium, or strontium substituting for calcium in the mineral structure. Pure wollastonite is bright white; the type and amount of impurities can produce gray, cream, brown, pale-green, or red colors.

Wollastonite’s Many Uses

Cannabis Research:

  • Wollastonite has already many well-known benefits in agriculture
  • Testing in a controlled way for the use in the cannabis industry.
  • Possibly the first in the industry to do trials.
  • Engaged AGRINOVA for Wollastonite Research and Development
  • Entered into a Distribution Agreement with AREV Brands, where Vertical will supply its St-Onge wollastonite to AREV for direct distribution to both small-scale craft growing operations and potentially larger-scale Health Canada approved companies directly involved in growing and processing cannabis and hemp.
  • Testing of Vertical’s St-Onge wollastonite on a range of important agricultural end uses will also be conducted
  • Became a member of the International Fertilizer Industry Association (IFA), as part of its ongoing efforts to promote and strategically market it’s world-class St-Onge wollastonite to a range of potential end-users.

Major Demand in Ceramics Industry:

  • Combination of high brightness and low gas release of Wollastonite when heated creates demand
  • Brilliant whiteness of importance to coatings and filler markets

Wollasatonite applications are endless

  • An industrial mineral comprised chemically of calcium, silicon and oxygen. Its molecular formula is CaSiO3 and its theoretical composition consists of 48.28% CaO and 51.72% SiO2.

St. Onge Wollastonite Deposit 2019

  • Twenty-three (23) drill holes totaling 1,784.0 metres were completed
  • Twenty (20) drill holes intersected high-grade wollastonite zones, confirming excellent continuity and correlation with the thickly mineralized zones intersected by previously reported historical drill holes.
  • Sixteen (16) drill holes intersected high-grade wollastonite zones right up until the end of the hole, which are all open at depth.
  • A total of 1,107.5 meters of high-grade wollastonite mineralized core length was intersected, representing approximately 62% of all drilled core length.

CLIENT FEATURE: Affinity Metals – Grab Samples Exceed Measurable Limits Prior to Drill Program $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca

Posted by AGORACOM at 12:15 PM on Monday, November 18th, 2019
  • Has now completed the drilling portion of the 2019 Regal exploration program at the Regal property, 1,846 meters of diamond drilling was completed in 21 holes.
  • Sampled 4,410g/t Silver, 5.68g/t Gold, 26.4% Zinc, 2.27% Copper, and >20% Lead.
  • 22 samples collected from the Black Jacket and Allco areas of the Regal property located approximately 35 km northeast of Revelstoke, BC.
  • The majority contained bonanza grade silver, zinc, and lead with many samples reaching assay over-limits. 
  • Further assaying of over-limits has been initiated, results will be reported once received.

Property History & Background

The property hosts numerous mineral occurrences including the following past-producing mines:

Snowflake and Regal Silver (Stannex/Woolsey) Mines

The Snowflake and Regal Silver mines were two former producing mines that operated intermittently during the period 1936-1953. The last significant work on the property took place from 1967-1970, when Stannex Minerals completed 2,450 meters of underground development work and a feasibility study, but did not restart mining operations. In 1982, reported reserves were 590,703 tonnes grading 71.6 grams per tonne silver, 2.66 per cent lead, 1.26 per cent zinc, 1.1 per cent copper, 0.13 per cent tin and 0.015 per cent tungsten (Minfile No. 082N 004 – Prospectus, Gunsteel Resources Inc., April 29, 1986). It should be noted that the above resource and grades, although believed to be reliable, were prepared prior to the adoption of NI43-101 and are not compliant with current standards set out therein for calculating mineral resources or reserves. 

ALLCO Silver Mine

The Allco Silver Mine is situated 6.35 Kilometers northwest of the above described Snowflake/Regal Mine(s) and is also part of the Affinity claim group.

The Allco Silver Mine operated from 1936-1937 and produced 213 tonnes of concentrates containing 11 troy ounces of gold (1.55 g/t), 11,211 troy ounces of silver (1,637 g/t) and 173,159 lbs of lead (36.9%). 

Airborne Geophysics to Guide Future Exploration

An extensive airborne geophysics survey conducted by Geotech Ltd of Aurora, Ontario, for Northaven Resources Corp. in 2011, identified four well defined high potential linear targets correlating with the same structural orientation as the Allco, Snowflake and Regal Silver mines. Northaven also reported that the mineralogy and structural orientation of the Allco, Snowflake and Regal Silver appeared to be similar to that of Huakan’s J&L gold project located to the north, and on a similar geophysical trend line. The J&L is reportedly now one of western Canada’s largest undeveloped gold mineral resources.

After completing the airborne survey, Northaven failed in financing their company and conducting further exploration on the property and subsequently forfeited the claims without any of the follow up work ever being completed. Affinity Metals is in the fortunate position of benefitting from this significant and promising geophysics data and associated targets.

The aforementioned Northaven airborne geophysical survey conducted at a cost of $319,458.95 in August of 2011 is described in The BC Ministry of Energy, Mines and Petroleum Resources Assessment Report #33054. The results of the survey are competently explained and illustrated by professionals on You Tube at: https://www.youtube.com/watch?v=GX431eBY_t0

FULL DISCLOSURE: Affinity Metals is an advertising client of AGORA Internet Relations Corp

Affinity Hub on Agoracom

CLIENT FEATURE: Advance Gold $AAX.ca – IP Survey Demonstrates Potential for Large System Beneath Tabasquena Mine Prior to Drill Program $SIL.ca $FA.ca $ANG.jo $ABX.ca $NGT.ca $MGG.ca $TECK.ca $FNLPF $PAAS.ca

Posted by AGORACOM at 11:28 AM on Monday, November 18th, 2019
https://www.advancegold.ca/site/templates/img/advance-gold.png
  • A 3D Induced Polarization (IP) geophysical survey on its Tabasquena project in Zacatecas, Mexico has outlined a significant continuous chargeability anomaly.
  • This anomaly now has an east-west width of approximately 400 to 500 metres and an apparent strike length of over 1000 metres.
  • The anomaly remains open to the north and to the south and at depth.
  • Drilling to commence once the IP survey has been completed.
The chargeability anomaly is approximately 250 metres below historical mining and was designed for 500 to 550 metres of vertical depth investigation.

The IP data also clearly shows that the large polarisable body/target is apparently quickly deepening northward and getting closer to surface southward. The IP anomaly starts at around 100 metres below the past drill hole intersections that contained widespread gold and silver mineralization in epithermal veins.

Tabasquena

  • Previous drilling found a network of veins with widespread gold and silver mineralization.
  • The first phase geophysical survey revealed a large chargeability anomaly right below these veins and is getting nearer to the surface as it trends south.
  • Geophysical advisor described the anomaly as ‘quite remarkable in its size and continuity.
  • Advance is in a region with very large mines, including the El Coronel open pit, 12 miles to the south of Tabasquena.

Advance Gold Hub on Agoracom

FULL DISCLOSURE: Advance Gold is an advertising client of AGORA Internet Relations Corp.

LOMIKO Metals $LMR.ca – Graphene: The More You Bend It, The Softer It Gets $CJC.ca $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

Posted by AGORACOM at 4:43 PM on Friday, November 15th, 2019

SPONSOR: Lomiko Metals LMR:TSX-V – A Canadian exploration-stage company discovered high-grade graphite at its La Loutre Property in Quebec and is working toward a Pre-Economic Assessment (PEA) that will increase its current indicated resource of 4.1 Mt of 6.5% Cg to over 10 Mt of 10%+ Cg through a 21 hole program at the Refractory Zone. Click Here For More Information

http://blog.agoracom.com/wp-content/uploads/2019/09/Lomiko-Square-Logo-1.png

New research by engineers at the University of Illinois combines atomic-scale experimentation with computer modeling to determine how much energy it takes to bend multilayer graphene—a question that has eluded scientists since graphene was first isolated. The findings are reported in the journal Nature Materials.

Graphene—a single layer of carbon atoms arranged in a lattice—is the strongest material in the world and so thin that it is flexible, the researchers said. It is considered one of the key ingredients of future technologies.

Most of the current research on graphene targets the development of nanoscale electronic devices. Yet, researchers say that many technologies—from stretchable electronics to tiny robots so small that they cannot be seen with the naked eye—require an understanding of the mechanics of graphene, particularly how it flexes and bends, to unlock their potential.

“The bending stiffness of a material is one of its most fundamental mechanical properties,” said Edmund Han, a materials science and engineering graduate student and study co-author. “Even though we have been studying graphene for two decades, we have yet to resolve this very fundamental property. The reason is that different research groups have come up with different answers that span across orders of magnitude.”

The team discovered why previous research efforts disagreed. “They were either bending the material a little or bending it a lot,” said Jaehyung Yu, a mechanical science and engineering graduate student and study co-author. “But we found that graphene behaves differently in these two situations. When you bend multilayer graphene a little, it acts more like a stiff plate or a piece of wood. When you bend it a lot, it acts like a stack of papers where the atomic layers can slide past each other.”

“What is exciting about this work is that it shows that even though everyone disagreed, they were actually all correct,” said Arend van der Zande, a professor of mechanical science and engineering and study co-author. “Every group was measuring something different. What we have discovered is a model to explain all the disagreement by showing how they all relate together through different degrees of bending.”

To make the bent graphene, Yu fabricated individual atomic layers of hexagonal boron nitride, another 2-D material, into atomic-scale steps, then stamped the graphene over the top. Using a focused ion beam, Han cut a slice of material and imaged the atomic structure with an electron microscope to see where each graphene layer sat.

The team then developed a set of equations and simulations to calculate the bending stiffness using the shape of the graphene bend. Graduate student Edmund Han, left, professor Elif Ertekin, graduate student Jaehyung Yu, professor Pinshane Y. Huang, front, and professor Arend M. van der Zande have determined how much energy it takes to bend multilayer graphene – a question that has long eluded scientists. Credit: Stephanie Adams

By draping multiple layers of graphene over a step just one to five atoms high, the researchers created a controlled and precise way of measuring how the material would bend over the step in different configurations.

“In this simple structure, there are two kinds of forces involved in bending the graphene,” said Pinshane Huang, a materials science and engineering professor and study co-author. “Adhesion, or the attraction of atoms to the surface, tries to pull the material down. The stiffer the material, the more it will try to pop back up, resisting the pull of adhesion. The shape that the graphene takes over the atomic steps encodes all the information about the material’s stiffness.”

The study systematically controlled exactly how much the material bent and how the properties of the graphene changed.

“Because we studied graphene bent by different amounts, we were able to see the transition from one regime to another, from rigid to flexible and from plate to sheet behavior,” said mechanical science and engineering professor Elif Ertekin, who led the computer modeling portion of the research. “We built atomic-scale models to show that the reason this could happen is that the individual layers can slip over each other. Once we had this idea, we were able use the electron microscope to confirm the slip between the individual layers.”

The new results have implications for the creation of machines that are small and flexible enough to interact with cells or biological material, the researchers said.

“Cells can change shape and respond to their environment, and if we want to move in the direction of microrobots or systems that have the capabilities of biological systems, we need to have electronic systems that can change their shapes and be very soft as well,” van der Zande said. “By taking advantage of interlayer slip, we have shown that the graphene can be orders of magnitude softer than conventional materials of the same thickness.”

Source: https://phys.org/news/2019-11-graphene-softer.html

CLIENT FEATURE: CardioComm Solutions $EKG.ca – Connecting Your Heart To The Cloud $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 12:49 PM on Friday, November 15th, 2019

Global Leaders in Mobile  ECG Connectivity

  • 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers
  • Sold into > 20 countries, with the largest customer base located in the US
  • Class II medical device clearances and device agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health
  • ECG solutions for both consumer (OTC) and medical (Rx) markets
  • Owns all IP and source code
  • Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring

Recent Highlights

  • Secured New Health Canada Device Clearance and Exclusive Canadian Sales Rights for US Medical ECG Device Manufacturer Read More
    • Entered into an exclusive sales and marketing agreement for the GEMS™ Sirona with California-based Datrix LLC
    • Under the multi-year, renewable agreement, CardioComm assumes the role of exclusive Canadian distributor of the Datrix ECG recorders under the GEMS™ Sirona brand device.
  • Secured Newest US and Canadian Medical Device 13485:2016 MDSAP Certification Read More
    • Completed its ISO 13485:2016 certification in compliance with the Medical Device Single Audit Program, a mandatory requiment under Health Canada and accepted as an equivalent quality management certification by the USA Food and Drug Administration.
  • Announced ECG Services Integration and Co-Marketing Agreement with California-Based BodiMetrics LLC Read More
    • GEMS™ Universal will be available under two subscription models:
    • $6 US per month with one free ECG interpretation included; and,
    • $69 US per year with 12 free ECG interpretations that may be requested any time during the one year subscription.

Company Accolades

FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.

Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:45 AM on Friday, November 15th, 2019
  • Successfully building BioPharma pipeline in high-value indications
  • Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
  • Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its financial results for the second quarter Fiscal Year 2020 ended September 30, 2019. The Company also provided an update on its corporate and clinical progress.

“We continue to push forward on all fronts as we work to establish Applied as a leader in the development and commercialization of novel, science-driven, synthetic endocannabinoid therapeutics / biopharmaceuticals and impact areas of significant unmet need,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Over the course of the past quarter, we have made notable strides on the corporate and clinical front and remain diligent in working to drive value for all stakeholders.”

“We continued to build out our BioPharma division and have established a Scientific Advisory Board of leading experts in the endocannabinoid space. We were pleased to have welcomed our inaugural members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an integral role as we look to optimize our therapeutic pipeline and look to make additional appointments in the near term to help drive this business unit forward. Additionally, we have continued to execute on our robust business development initiatives and remain in late-stage discussions to in-license our product candidates that we believe have the potential to address a number of areas with significant unmet need. In tandem, we continue to remain opportunistic in accessing the necessary non-dilutive funding and capital through strategic investments from which we believe will provide us with the foundation and momentum to move forward.”

Applied BioPharma: developing science-driven synthetic cannabinoid therapeutics that satisfy unmet medical needs and continue to drive innovation in the endocannabinoid space.

The Applied BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS).

Applied Biopharma has to date developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions.

  • Applied expects to advance the first of its preclinical programs into open INDs in 2020.
    • ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
    • ABP-1901, its lead CB2 inverse agonist, which has demonstrated effectiveness in limiting or reversing damage due to neuroinflammation.
  • Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

Applied Products: portfolio of consumer, animal health, women’s health and sports medicine of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-U.S. countries.

The Applied Products business unit is focused on maximizing top-line revenue through selective investments in product lines and marketing campaigns (increase share-of-voice), continually reevaluating the endocannabinoid Health & Wellness environment for opportunities and developing and implementing a nutraceutical strategy.

Applied Products has seen a modest year-over-year increase in top line revenue. At this time the Board, with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require significant resource and capital allocations, is evaluating various strategic options for this business unit.

Trace Analytics, Inc: Applied’s majority owned subsidiary scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing.

In July 2019, Trace Analytics was contracted for services with the Washington State Department of Agriculture (WSDA). This contract includes testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.

Upcoming Milestones Expected to Drive Value

  • Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
  • Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
  • Finalize and execute on the strategic options for Applied Products.
  • Successfully execute overall strategy of the Company and business development efforts.
  • Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
  • Uplist to a National Exchange.

Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019

For the quarter ended September 30, 2019, the Company reported net loss of approximately $777,746 or net loss per diluted share of $0.06, compared to a net loss of approximately $110,423 or a net loss per diluted share of $0.01, for the quarter ended September 30, 2018.

The Company reported revenues from Applied BioSciences’ CBD product lines was $169,654 and $59,400 during the six months ended September 30, 2019 and 2018, respectively. The increase reflects higher sales across all of the Company’s CBD brand product lines, most notably in its topical products, combined with expansion into sales of bulk hemp seed and raw CBD. Service revenue resulting from the Company’s lab testing is attributed solely to the acquisition of Trace Analytics in January 2019, and totaled $286,077 for the six months ended September 30, 2019.

General and administrative expenses increased $519,140 to $707,192 for the three months ended September 30, 2019 as compared to $188,052 for the three months ended September 30, 2018. The increase was mainly attributable to the acquisition of Trace Analytics and addition of our Applied BioPharma subsidiary, with general and administrative expenses for the remainder of the Company.

The Company ended the quarter with $73,412 in cash and cash equivalents. The Company is actively evaluating opportunities to fund continued growth in its products and services revenue along with planned business development activities for Applied BioPharma and anticipates closing a financing by the end of first quarter Fiscal Year 2020.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Applied BioSciences $APPB – New, Online Resource Designed to Assist Pharmacists With CBD Products $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 2:30 PM on Thursday, November 14th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

The National Community Pharmacists Association (NCPA) has launched a new resource for pharmacists looking to understand and purchase reliable cannabidiol (CBD) products, called the NCPA CBD Source.

The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab. The site also features experts that pharmacists can contact with questions regarding buying, selling, and marketing. In addition, pharmacists will be able to evaluate each company included in the resource, as well as see each company’s products.

CBD products have exploded in recent months following the Hemp Farming Act of 2018, which removed hemp from the list of Schedule I controlled substances. According to a statement from NCPA, the United States CBD industry grew by nearly 40% in 2017, and is expected to reach $22 billion by 2024.

CBD can help relieve pain and inflammation resulting from chronic illnesses, as well as boost the immune system, and these effects have led to a flood of patient interest.

“Many pharmacies are deciding to sell CBD products because of the patient demand and because, as the medication expert, they can serve as the source of truth,” said NCPA CEO B. Douglas Hoey, RPh, MBA.

Carter High, PharmD, of Best Value Rhome Pharmacy, said he plans on using the service to bolster the knowledge and products that he already trusts. CBD products are new to the pharmacy wheelhouse, High said, and he gets many phone calls with sales pitches from various CBD companies.

“It gets a little confusing as to whether or not they’re just talking a really good sales pitch, or if they really do have a genuine product,” High said.

High said it’s important for pharmacists to make sure they understand the uses and mechanisms of CBD products, but that this can be challenging given the crowded marketplace.

“Understanding just how CBD affects the body is a very good avenue for a pharmacist to delineate themselves as a knowledge expert on a new upcoming way of how to help patients out,” High said. “A marketplace such as [NCPA CBD Source] fills a very big gap that was missing, and helps from an efficiency standpoint at the store level.”

While he is excited to use the resources provided, High did emphasize that it doesn’t relieve pharmacists of the responsibility to ensure that the products are reliable, safe, and right for each patient. It does, however, help reassure pharmacists that the decisions they are making are the right ones, he added.

REFERENCE

NCPA, PRS Launch First-of-its-Kind “CBD Source” Tool for Pharmacists

https://www.ncpanet.org/newsroom/news-releases/2019/10/29/ncpa-prs-launch-first-of-its-kind-cbd-source-tool-for-pharmacists.

New Age Metals $NAM.ca – Sales Revenue of #Palladium to Soar in the Near Future Owing to Growing Consumer Adoption $WG.ca $XTM.ca $WM.ca $PDL.ca

Posted by AGORACOM-JC at 12:59 PM on Thursday, November 14th, 2019

SPONSOR: New Age Metals Inc. The company’s Lithium Division has already made significant acquisitions in Canada and the USA. The company also owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces in the Inferred. Learn More.

Sales Revenue of Palladium to Soar in the Near Future Owing to Growing Consumer Adoption

  • Global market for palladium is likely to experience significant growth with declining demand for metals and increasing demand for recycling metals, leading to palladium demand outstripping the supply.
  • In addition, changing prospects of investments in palladium have also contributed to the growth of the market

By: PMR Research

Palladium is a lustrous silvery-white rare metal used in a diverse range of applications. The metal with other elements such as osmium, iridium, ruthenium, rhodium, and platinum are referred to as Platinum Group Metals (PGM). Palladium is majorly consumed in the automotive industry as catalytic converters, manufacturing of electronics and jewelry, as well as chemical and dental applications. Palladium is sourced from two major sources, viz., mine production and recycling.

The global market for palladium is likely to experience significant growth with declining demand for metals and increasing demand for recycling metals, leading to palladium demand outstripping the supply. In addition, changing prospects of investments in palladium have also contributed to the growth of the market. Several new palladium exchange-traded funds by companies such as Absa Capital in South Africa are expected to create a significant boost for the palladium market.

Growing demand for palladium in catalytic converters in the automotive industry in vehicles exhausts are one of the major growth factors driving the palladium market. Demand for the metal from other sectors such as jewelry and industrial are also anticipated to contribute to the growth of the market. However, rising prices of palladium owing to supply issues in South Africa and declining state stockpiles in Russia are expected to hamper the growth of the market. North America was the largest consumer for palladium, followed by China owing to the presence of the vast automotive industry in the region. Future market growth is expected to be from Asia Pacific with the growing industrial activities in emerging economies such as India. These factors are expected to provide new opportunities for the growth of the market.

Source: https://www.zebvo.com/2019/11/14/sales-revenue-of-palladium-to-soar-in-the-near-future-owing-to-growing-consumer-adoption/